LeMaitre Vascular Competitors

LeMaitre Vascular (NASDAQ:LMAT) and ShockWave Medical (NASDAQ:SWAV) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Valuation & Earnings

This table compares LeMaitre Vascular and ShockWave Medical's revenue, earnings per share (EPS) and valuation.

LeMaitre Vascular has higher revenue and earnings than ShockWave Medical. ShockWave Medical is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for LeMaitre Vascular and ShockWave Medical, as provided by MarketBeat.

LeMaitre Vascular presently has a consensus target price of $36.1667, suggesting a potential downside of 29.62%. ShockWave Medical has a consensus target price of $109.50, suggesting a potential downside of 6.22%. Given ShockWave Medical's higher probable upside, analysts clearly believe ShockWave Medical is more favorable than LeMaitre Vascular.

Risk and Volatility

LeMaitre Vascular has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500. Comparatively, ShockWave Medical has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500.

Insider and Institutional Ownership

84.2% of LeMaitre Vascular shares are owned by institutional investors. Comparatively, 88.8% of ShockWave Medical shares are owned by institutional investors. 16.5% of LeMaitre Vascular shares are owned by insiders. Comparatively, 15.3% of ShockWave Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares LeMaitre Vascular and ShockWave Medical's net margins, return on equity and return on assets.

Summary

LeMaitre Vascular beats ShockWave Medical on 11 of the 14 factors compared between the two stocks.

Cantel Medical (NYSE:CMD) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for Cantel Medical and LeMaitre Vascular, as reported by MarketBeat.com.

Cantel Medical presently has a consensus price target of $71.50, suggesting a potential downside of 3.74%. LeMaitre Vascular has a consensus price target of $36.1667, suggesting a potential downside of 29.62%. Given Cantel Medical's higher possible upside, equities research analysts plainly believe Cantel Medical is more favorable than LeMaitre Vascular.

Volatility & Risk

Cantel Medical has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500.

Profitability

This table compares Cantel Medical and LeMaitre Vascular's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Cantel Medical and LeMaitre Vascular's top-line revenue, earnings per share and valuation.

LeMaitre Vascular has lower revenue, but higher earnings than Cantel Medical. Cantel Medical is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

95.0% of Cantel Medical shares are owned by institutional investors. Comparatively, 84.2% of LeMaitre Vascular shares are owned by institutional investors. 10.7% of Cantel Medical shares are owned by company insiders. Comparatively, 16.5% of LeMaitre Vascular shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

LeMaitre Vascular beats Cantel Medical on 8 of the 14 factors compared between the two stocks.

Merit Medical Systems (NASDAQ:MMSI) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for Merit Medical Systems and LeMaitre Vascular, as reported by MarketBeat.com.

Merit Medical Systems presently has a consensus price target of $64.3750, suggesting a potential upside of 15.53%. LeMaitre Vascular has a consensus price target of $36.1667, suggesting a potential downside of 29.62%. Given Merit Medical Systems' stronger consensus rating and higher possible upside, equities research analysts plainly believe Merit Medical Systems is more favorable than LeMaitre Vascular.

Volatility & Risk

Merit Medical Systems has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500.

Profitability

This table compares Merit Medical Systems and LeMaitre Vascular's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Merit Medical Systems and LeMaitre Vascular's top-line revenue, earnings per share and valuation.

LeMaitre Vascular has lower revenue, but higher earnings than Merit Medical Systems. Merit Medical Systems is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

99.5% of Merit Medical Systems shares are owned by institutional investors. Comparatively, 84.2% of LeMaitre Vascular shares are owned by institutional investors. 4.7% of Merit Medical Systems shares are owned by company insiders. Comparatively, 16.5% of LeMaitre Vascular shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

LeMaitre Vascular beats Merit Medical Systems on 8 of the 14 factors compared between the two stocks.

NuVasive (NASDAQ:NUVA) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Insider and Institutional Ownership

84.2% of LeMaitre Vascular shares are owned by institutional investors. 0.9% of NuVasive shares are owned by company insiders. Comparatively, 16.5% of LeMaitre Vascular shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for NuVasive and LeMaitre Vascular, as reported by MarketBeat.com.

NuVasive presently has a consensus price target of $60.4667, suggesting a potential upside of 0.23%. LeMaitre Vascular has a consensus price target of $36.1667, suggesting a potential downside of 29.62%. Given NuVasive's higher possible upside, equities research analysts plainly believe NuVasive is more favorable than LeMaitre Vascular.

Volatility & Risk

NuVasive has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500.

Profitability

This table compares NuVasive and LeMaitre Vascular's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares NuVasive and LeMaitre Vascular's top-line revenue, earnings per share and valuation.

NuVasive has higher revenue and earnings than LeMaitre Vascular. NuVasive is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Summary

LeMaitre Vascular beats NuVasive on 9 of the 14 factors compared between the two stocks.

AtriCure (NASDAQ:ATRC) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.

Insider & Institutional Ownership

94.7% of AtriCure shares are held by institutional investors. Comparatively, 84.2% of LeMaitre Vascular shares are held by institutional investors. 5.8% of AtriCure shares are held by company insiders. Comparatively, 16.5% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for AtriCure and LeMaitre Vascular, as reported by MarketBeat.

AtriCure currently has a consensus price target of $66.00, suggesting a potential upside of 1.12%. LeMaitre Vascular has a consensus price target of $36.1667, suggesting a potential downside of 29.62%. Given AtriCure's stronger consensus rating and higher possible upside, research analysts clearly believe AtriCure is more favorable than LeMaitre Vascular.

Risk and Volatility

AtriCure has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500.

Profitability

This table compares AtriCure and LeMaitre Vascular's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares AtriCure and LeMaitre Vascular's top-line revenue, earnings per share (EPS) and valuation.

LeMaitre Vascular has lower revenue, but higher earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Summary

LeMaitre Vascular beats AtriCure on 8 of the 14 factors compared between the two stocks.

Inovio Pharmaceuticals (NASDAQ:INO) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.

Insider & Institutional Ownership

36.0% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 84.2% of LeMaitre Vascular shares are held by institutional investors. 4.0% of Inovio Pharmaceuticals shares are held by company insiders. Comparatively, 16.5% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Inovio Pharmaceuticals and LeMaitre Vascular, as reported by MarketBeat.

Inovio Pharmaceuticals currently has a consensus price target of $15.3333, suggesting a potential upside of 38.14%. LeMaitre Vascular has a consensus price target of $36.1667, suggesting a potential downside of 29.62%. Given Inovio Pharmaceuticals' higher possible upside, research analysts clearly believe Inovio Pharmaceuticals is more favorable than LeMaitre Vascular.

Risk and Volatility

Inovio Pharmaceuticals has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500.

Profitability

This table compares Inovio Pharmaceuticals and LeMaitre Vascular's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Inovio Pharmaceuticals and LeMaitre Vascular's top-line revenue, earnings per share (EPS) and valuation.

LeMaitre Vascular has higher revenue and earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Summary

LeMaitre Vascular beats Inovio Pharmaceuticals on 11 of the 13 factors compared between the two stocks.